Bio-engineered Stent Market By Material Type (Medical-grade Stainless Steel, Cobalt-Chromium Alloy, Others), By Disease Indication (Coronary Heart Disease, Ischemic Heart Disease, Peripheral Artery Disease, Other), By End-User Segment (Hospitals, Specialty Clinics, Ambulatory Surgical Centers) - Growth, Future Prospects, and Competitive Analysis, 2019 - 2027

The bio-engineered stent market is expected to exhibit dynamic growth during the forecast period.

The global bio-engineered stent market is growing proficiently and is expected to grow at a CAGR of 7.1%. Globally, the growing prevalence of coronary heart disease and other hearing-related disorders will drive market growth. Growing awareness about new medical technology and the launch of advanced bio-engineered cardiac stents or coronary stents with integrated biological solutions and enhanced biomaterials are factors driving the overall growth of the bio-engineered stent market on a global scale.

Market Synopsis

The medical-grade stainless steel segment is expected to register higher growth by the end of 2027.

Advancements in biodegradable metals for cardiovascular stents, along with developments in the field of alloys, will enhance the overall growth of the market. Metallic stents are usually used to endorse revascularization and preserve the patency of damaged arteries following angioplasty procedures. The intrinsic surface and mechanical properties of metals make them more attractive. For e.g., the Genus Bio-engineered Stent has an exceptional dual helix design that delivers natural conformability and has endothelial progenitor cell capture technology to defend against thrombus (blood clotting) and minimize the recurrence of abnormal narrowing of an artery or valve by accelerating the natural restorative process.

Coronary heart diseases to witness a significant CAGR.

Increasing hospital admissions for coronary heart-related disorders and their treatment generated the largest revenue share in 2018. Additionally, a large patient pool with cardiovascular diseases and individuals for the early diagnosis of heart-related conditions on a global scale will drive the market growth globally. In 2017, according to statistics from the American College of Cardiology, cardiovascular disease accounted for more than 800,000 deaths in the United States. Additionally, the increasing prevalence of acute coronary syndrome, ischemic heart disease, and peripheral artery disease will drive the demand for the bio-engineered stent market. Advancements in bioengineering technology, FDA approval of new products, an increasing geriatric population, and increased awareness offer potential advantages as an elective treatment to high-cost cardiac surgical procedures and wide usage of top applications in the stent industry.

The increasing geriatric population, FDA approval, and the presence of top manufacturers hold North America in a dominant position.

In 2018, the U.S. produced maximum revenue in the bio-engineered stent market due to an increase in the prevalence of cardiovascular disorders, increasing hospital admissions for the treatment of coronary heart disease, and the launch of new products that will boost market growth. Presently, more than 92 million U.S. citizens are living with some form of cardiovascular condition or the after-effects of a stroke. According to a 2016 study by the American Heart Association, overall direct medical expenditures for cardiovascular diseases are projected to surge to around $749 billion in 2035 globally. The existence of numerous treatment options further increases patient compliance with the safety and efficiency of treatment for cardiovascular-related disorders, which is expected to drive market growth. However, the higher expense of surgical procedures, less popularity among physicians in the developed regions, complexity in R&D, and controlled returns may hamper the overall market growth on a global scale.

Increased research and development with strong product pipelines in the developed regions

Major players in the bio-engineered stent market are ORBUSNEICH MEDICAL, Medtronic, plc., Abbott Laboratories, Vascular Concepts, C. R. Bard, Lombard Medical Technologies, Biotronik SE & Co. KG, Terumo Corporation, Endologix, Inc., Translumina GmbH, and others. Major companies are emerging with advanced technologies and integrated biological solutions. Acquisitions, partnership agreements, and enhanced R&D on medical technology will invent the development of the bio-engineered stent market in emerging nations in the near future.

Historical and Forecast Period

This study report represents the analysis of each segment from 2017 to 2027, considering 2018 to be the base year. The compound annual growth rate (CAGR) for each of the respective segments is estimated for the forecast period from 2019 to 2027.

Market Segmentation

The current report also encompasses qualitative and qualitative market valuation factors such as key market drivers, market trends, restraints, and opportunities that give a better understanding of the overall bio-engineered stent market. Additionally, the global report also comprises a graphical representation of the competitive landscape based on their market initiatives and strategies, product portfolios, and business strengths.

Key questions are answered in this report.

  • What are the current market trends and dynamics in the bio-engineered stent market, and what are the valuable opportunities for emerging players?
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which material type segment holds a larger market share and why?
  • Are low- and middle-income economies investing in the bio-engineered stent market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and the Middle East and Africa?

 Frequently Asked Questions:

The market for Bio-engineered Stent Market is expected to reach in XX Bn in 2027.

The Bio-engineered Stent Market is expected to see significant CAGR growth over the coming years, at 7.1%.

The report is forecasted to 2019-2027.

The base year of this report is 2018.

ORBUSNEICH MEDICAL,Medtronic, plc.,Abbott Laboratories,Vascular Concepts,C. R. Bard are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Aug 2019
Category:  Medical Devices
Report ID:   59855
Report Format:   PDF
Pages:   120
Rating:    4.1 (66)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support